



Summit BioAnalytics | Nassau, The Bahamas | lab@summitbioanalytics.com |
summitbioanalytics.com

TESTED FOR

Iron Within Research

SAMPLE

Tesamorelin / Ipamorelin — 10 mg

PASS

BATCH #

IWR-2607-
TSMIPA10

PURITY

99.75%

MASS

10.54 mg

IDENTITY

Confirmed

COA #:

SBA-26-0060

Method:

Full QC Panel

Lot Number:

IWR-2607-
TSMIPA10

Analysis Date:

2026-08-02

Date Received:

2026-07-29

Labeled Content:

10 mg

Appearance:

White lyophilized
powder, intact seal



SCAN TO VERIFY



Identity



Purity



Endotoxins



Fentanyl Free



VIAL CAP

Black

#010101

CLOSURE AS
RECEIVED

Test	Specification	Result
Identity	Ipamorelin + Tesamorelin	All confirmed
Purity (HPLC, aggregate)	>= 98.0%	99.75%

Test	Specification	Result
Blend Composition	Report only	Quantified – see composition
Content (gross)	Report only	10.54 mg
Fentanyl Screen (LC-MS/MS)	Not detected	Not detected
Endotoxins (LAL)	Report Result	0.07 EU/mL
Sterility Screen (rapid PCR)	No growth	No growth
Heavy Metals (ICP-MS)	ICH Q3D limits	All analytes within limits

Qualitative and quantitative chemical analysis by RP-HPLC with UV detection; identity confirmed by LC-MS. Fentanyl screening by targeted LC-MS/MS. Sterility by rapid nucleic-acid amplification — a screening method, not compendial sterility per USP <71>. Full methodology available on request.

BLEND COMPOSITION

Mass basis, per-component reference standards

COMPONENT	AMOUNT	SHARE OF TOTAL	IDENTITY
Ipamorelin	5.20 mg	49.34%	Confirmed
Tesamorelin	5.34 mg	50.66%	Confirmed

Each component is quantified on a mass basis against its own reference standard. Share of total will not match a component's area-percent in the chromatogram — different chromophores respond differently at the monitoring wavelength. Amounts are reported as measured; this certificate does not assess them against a declared formulation.

Kasey Malganius

Kasey Malganius
Lab Director
2026-08-02

COA #:SBA-26-0060

Access Code:MPQJ7L4A

Analyst:R. Whitfield

Verify:summitbioanalytics.com/verify

Issued:2026-08-02